Neuren Fragile X Study of trofinetide (NNZ-2566) – New sites and video

Three new sites recently joined Neuren Pharmaceuticals’ clinical trial of trofinetide (NNZ-2566) for adolescent and adult males with Fragile X, including UC Davis, led by Dr. Randi Hagerman, Cincinnati Children’s Hospital, led by Dr. Craig Erickson, and Geisinger Medical Center (led by Dr. T. Challman). The study is still recruiting participants. Further details and participating sites can be found at www.fragilexstudy.org

 

New Video on trofinetide’s Mechanism of Action

neuren-videoNeuren has also released a video that describes the mechanism of action of trofinetide (NNZ-2566). The video presents the biological rationale for the use of trofinetide in Fragile X syndrome and other neuro-developmental disorders, and highlights what makes trofinetide different from other compounds in current or recent trials for the treatment of Fragile X symptoms. Watch it at www.neurenpharma.com

This experimental compound is currently also being studied as a potential treatment for Rett Syndrome (see article by Dr. Michael Tranfaglia, FRAXA Medical Director) and Traumatic Brain Injury.

For other studies seeking participants with Fragile X, please FRAXA’s clinical trials page.

If you are a parent of someone with Fragile X and would like to join a survey study online to help us improve future trial design (no travel needed), please visit http://geisingeradmi.org/care-innovation/studies/fragile-x-family-history-study/.